2029 Clinical Development Research 
Broad Institute
MAY 9, 2024
Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery. Terms of the agreement were not disclosed. “We
The Pharma Data
JANUARY 20, 2021
CytomX expects to use the net proceeds from this offering to further develop its proprietary Probody ® therapeutics pipeline and research. CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody-drug conjugates due to their presence on many healthy tissues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Vial
MARCH 1, 2024
Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). billion by 2029. ’s services include supporting life sciences research, analytical solutions, and diagnostics or developing and manufacturing therapeutic interventions.
The Pharma Data
OCTOBER 9, 2021
Bristol Myers Squibb continues to expect greater than $4 billion non-risk adjusted revenue target for deucravacitinib in 2029. Due to the innovative design of deucravacitinib, Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for the science underpinning the clinical development of deucravacitinib.
The Pharma Data
JANUARY 25, 2021
Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
Expert insights. Personalized for you.
52 
Let's personalize your content